Evidence map›Paper›PMID 31367274›Full record

ArticleWorld journal of gastrointestinal oncology2019

TYMS/KRAS/BRAF molecular profiling predicts survival following adjuvant chemotherapy in colorectal cancer.

Anastasios Ntavatzikos, Aris Spathis, Paul Patapis, Nikolaos Machairas, Georgia Vourli, George Peros, Iordanis Papadopoulos, Ioannis Panayiotides, Anna Koumarianou

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastrointestinal oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Anastasios NtavatzikosHematology-Oncology Unit, 4th Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, "ATTIKON" University Hospital, Athens 12462, Greece. dmaal2@yahoo.gr.
Aris SpathisDepartment of Cytopathology, National and Kapodistrian University of Athens, Medical School, "ATTIKON" University Hospital, Athens 12462, Greece.
Paul Patapis3 Department of Surgery, Medical School, National and Kapodistrian University of Athens, "ATTIKON" University Hospital, Athens 12462, Greece.
Nikolaos Machairas3 Department of Surgery, Medical School, National and Kapodistrian University of Athens, "ATTIKON" University Hospital, Athens 12462, Greece.
Georgia VourliDepartment of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, Athens 11527, Greece.
George PerosDepartment of Surgery, Medical School, National and Kapodistrian University of Athens, Evgenideio Therapeutirio S.A., "I AGIA TRIAS", Athens 11528, Greece.
Iordanis PapadopoulosDepartment of Surgery, Medical School, National and Kapodistrian University of Athens, Evgenideio Therapeutirio S.A., "I AGIA TRIAS", Athens 11528, Greece.
Ioannis Panayiotides2 Department of Pathology, University of Athens, Medical School, "ATTIKON" University Hospital, Athens 12462, Greece.
Anna KoumarianouHematology-Oncology Unit, 4th Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, "ATTIKON" University Hospital, Athens 12462, Greece.
National and Kapodistrian University of Athens · GRPalmetto Hematology Oncology · USAthens State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with stage II-III colorectal cancer (CRC) treated with adjuvant chemotherapy, gain a 25% survival benefit. In the context of personalized medicine, there is a need to identify patients with CRC who may benefit from adjuvant chemotherapy. Molecular profiling could guide treatment decisions in these patients. Thymidylate synthase (

aimTo investigate the association of

methodsA retrospective study studied formalin-fixed paraffin-embedded tissues (FFPEs) of consecutive patients treated with adjuvant chemotherapy during January/2005-January/2007. FFPEs were analysed with PCR for the detection of

resultsOne hundred and thirty patients with early stage CRC (stage I-II: 55 patients; stage III 75 patients; colon: 70 patients; rectal: 60 patients) were treated with surgery and chemotherapy. The 5-year disease free survival and overall survival rate was 61.6% and 73.9% respectively. 5'UTR polymorphisms of intermediate

conclusionProspective validating studies are required to confirm whether 2RG/3RG, 2RG/LOH, 3RC/LOH, absence of ins/LOH and wild type

Indexed as

BRAFColorectal neoplasmsFluorouracilKRASPrognosisThymidylate synthaseUntranslated regions

Identifiers

PMID31367274
PMCPMC6657223
OpenAlexW2957009233

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.